Supernus Pharmaceuticals, Inc.
$44.03
+0.011%Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -64.8).
Valuation inputs: P/E -64.8, earnings yield N/A, momentum +0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -3.6%, ROIC -2.6%).
Profitability stack: net margin -5.4%, ROE -3.6%, ROIC -2.6%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +26.9%, momentum +0.0%, net margin -5.4%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Supernus Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Supernus Pharmaceuticals, Inc. Fair Value Envelope
Supernus Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Supernus Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Supernus Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Strong liquidity. The company has adequate resources to meet short-term liabilities.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Supernus Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that SUPN stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 60.00, with estimates ranging from a low of 55.00 to a high of 65.00.
The consensus 1-year price target stands at 60.00, with estimates ranging from a low of 55.00 to a high of 65.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Supernus Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $20.07M worth of SUPN shares, with no buying activity reported.
3 Months
0
0.00
112.1K
5.68M
-5.7M
-$5.68M
3-6 Months
0
0.00
16.9K
880.98K
-881K
-$881K
6-9 Months
0
0.00
121.1K
5.76M
-5.8M
-$5.76M
9-12 Months
0
0.00
176.0K
7.75M
-7.7M
-$7.75M
Top Buyers
No buying activity
Top Sellers
Khattar Jack A.
Director, Officer: President, Ceo
$12.47M
Bhatt Padmanabh P.
Officer: Sr. Vp Of Ip, Cso
$3.47M
Mottola Frank
Officer: Svp, Chief Tech. Ops. Officer
$1.19M
Gemayel Georges
Director
$1.00M
Dec Timothy C
Officer: Senior Vice-President & Cfo
$524K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $20.07M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
SUPN has not reported any dividend yield values in the available annual periods.
supn Dividend History
Learning Layer
Related Guides
Build conviction on SUPN by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.